ADVAXIS INC (ADXS)

Common Stock

0.155  -0.08 (-35.42%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ADVAXIS INC

NASDAQ:ADXS (12/23/2021, 11:39:10 AM)

0.155

-0.08 (-35.42%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-68.3%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap22.57M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ADXS Daily chart

Company Profile

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Monmouth Junction, New Jersey and currently employs 18 full-time employees. The company went IPO on 2005-07-28. The firm is using its Lm platform directed against tumor-specific targets to engage the patient's immune system to destroy tumor cells. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Its Lm platform technology has clinical activity in several programs. These Lm strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment (TME) to enable the T-cells to eliminate tumors.

Company Info

ADVAXIS INC

9 Deer Park Drive, Suite K-1

Monmouth Junction NEW JERSEY 08540

P: 17325451590.0

CEO: Kenneth Berlin

Employees: 18

Website: https://www.advaxis.com/

ADXS News

News Image7 months ago - Ayala PharmaceuticalsAyala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
News Image7 months ago - Ayala PharmaceuticalsAyala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations

MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced...

News Image8 months ago - Ayala PharmaceuticalsAyala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
News Image8 months ago - Ayala PharmaceuticalsAyala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced...

News Image9 months ago - Ayala PharmaceuticalsAyala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
News Image10 months ago - Ayala PharmaceuticalsImmunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile

ADXS Twits

Here you can normally see the latest stock twits on ADXS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example